Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H3 antibody-drug conjugate HS-20093

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently linked to a topoisomerase inhibitor (TOPOi), with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC HS-20093, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding and internalization, the TOPOi is released, and inhibits DNA topoisomerase activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is an immunoregulatory protein overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.
Synonym:anti-B7-H3 ADC HS-20093
anti-B7H3 ADC HS-20093
Code name:GSK 5764227
GSK-5764227
GSK5764227
HS 20093
HS-20093
HS20093
Search NCI's Drug Dictionary